A new analysis in the journal AIDS has reached a conclusion few will find unexpected -- newer, once-daily, fixed-dose antiretroviral regimens like Epzicom, Atripla, and Truvada are more durable than earlier antiretroviral treatment options. 'Our results indicate this [improved durability is] due to both more convenient dosing and improved tolerability of modern antiretroviral regimens,' they conclude. Prolonging the durability of antiretroviral regimens is critical to achieving long-term treatment success since the medications must be taken indefinitely, the study authors say.
